News Headlines

  1. CMC Pharmaceuticals, Inc. Announces Launch Of cGMP Laboratory Services
    9/17/2019

    CMC Pharmaceuticals, a leading provider of drug product development services, announces the addition of current Good Manufacturing Practices (cGMP) lab services at its Solon, OH location on October 1st. This addition includes the upgrading of laboratory SOPs and documentation practices to comply with U.S. FDA guidelines.

  2. AMPAC Fine Chemicals And SK Biotek Become New US Corporation Focused On Expanded Support To The World's Pharmaceutical Industry
    9/16/2019

    SK Holdings, the holding company of South Korea's SK Group, has established SK pharmteco, a U.S.-based Contract Manufacturing Organization (CMO) supporting Pharmaceutical Customers worldwide.

  3. Major Grant Awarded To Wistar Supports Development Of A Novel Therapeutic Approach For Antibiotic-Resistant Bacteria
    9/12/2019

    Antimicrobial resistance (AMR) represents an expanding global public health concern. While antibiotic-resistant organisms are appearing at an alarming rate, there has been a 30-year hiatus in the development of novel classes of antibiotics for combatting these infections.

  4. Aristea Therapeutics Announces Formation Of Scientific Advisory Board
    9/12/2019

    Aristea Therapeutics (Aristea), a clinical-stage drug development company developing novel therapies to treat serious inflammatory diseases, today announced the formation of its Scientific Advisory Board (SAB), which is comprised of industry experts in inflammatory and dermatological disease drug development

  5. Mallinckrodt Agrees To Sell BioVectra Inc. To H.I.G. Capital For $250M
    9/10/2019

    Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced it has entered into a definitive agreement to sell its wholly owned subsidiary BioVectra Inc. to an affiliate of H.I.G. Capital, a leading global private equity investment firm, for approximately $250 million, including fixed consideration of $175 million, comprised of an upfront payment of $135 million and a long-term note for $40 million, and contingent payments of up to $75 million, enabling Mallinckrodt to capture future BioVectra growth potential.

  6. FUJIFILM Irvine Scientific Launches BalanCD Gal Supplement For Biotherapeutic Development
    9/10/2019

    FUJIFILM Irvine Scientific, Inc., a world leader in the optimization, development and manufacture of cell culture media and industrial cell culture solutions, recently introduced BalanCD Gal Supplement.

  7. Ascensus Specialties To Acquire Callery
    9/6/2019

    Wind Point Partners (“Wind Point”) and Ascensus Specialties LLC (“Ascensus”) announced recently that Ascensus has signed a definitive agreement to acquire Callery, LLC (“Callery” or the “Company”). Callery is the leading global producer of boranes and specialty alcoholates.

  8. Sumitomo Dainippon Pharma And Roivant Sciences Enter Into A Memorandum Of Understanding To Create Broad Strategic Alliance To Deliver Promising New Medicines To Patients
    9/5/2019

    Sumitomo Dainippon Pharma Co., Ltd. (TSE: 4506), a leading Japanese pharmaceutical company, and Roivant Sciences Ltd., a technology-enabled healthcare company, today announced that they have entered into the Memorandum for the creation of a novel and broad Alliance to include the transfer to Sumitomo Dainippon Pharma of Roivant's ownership interests in 5 of their biopharmaceutical companies ("Vants"), with options to acquire up to 6 additional Vants, and access to Roivant's proprietary technology platforms, DrugOme and Digital Innovation.

  9. Velesco Pharma Set For Clinical Manufacturing Capacity Expansion
    9/3/2019

    Pharmaceutical development and clinical manufacturing expert, Velesco Pharma, is set to triple its clinical manufacturing capacity with the purchase and fit-out of a new, state-of-the-art facility in Wixom, Michigan.

  10. Ajinomoto Bio-Pharma Services Acquires Remaining Interest In Granules OmniChem Joint Venture In India
    8/29/2019

    Ajinomoto Bio-Pharma Services (“Aji Bio-Pharma”), a leading provider of biopharmaceutical contract development and manufacturing services, announced recently its intention to purchase the remaining 50 percent ownership interest in its Visakhapatnam, India joint venture, Granules OmniChem Private Limited (GOC) from its joint venture partner, Granules India Limited.